AIFF

Firefly Neuroscience Inc (AIFF) | Rumor.io

Firefly Neuroscience

AIFF

Attention (50-day avg)0%

Attention rank (50-day avg)#1,496

Bullish sentiment (50-day avg)80%

Price to earnings ratio-0.86

Market capitalization26.5M

Earnings per share-0.51

Dividend yield (TTM)—

Revenue (annual)1.1M

Net income (annual)-19.9M

Social

What share of all stock conversation is about AIFF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0% +0	0% 0

Sep 28

The company's AI-driven neuroscience platform has shown strong revenue growth, with a 71.9% year-over-year quarterly increase.
The stock has broken out on strong volume and shown momentum, with a clean bullish pattern and RSI staying heated.
The $1.55 area has been decisively broken, with the stock surging to $2.01 on roughly 144M shares, and a next target of $2.10.

Generated by AI

Sentiment

Of the messages about AIFF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +16.67	81.82% +41.82	80.41% +5.41	66.26% -8.96
Bearish	0% -16.67	18.18% -41.82	19.59% -5.41	33.74% +8.96

Bullish· Sep 25

$AIFF has broken out and is expected to continue its upward momentum.
Firefly Neuroscience's recent news is solid and has the potential to drive the stock price up to $3.50 by the end of Monday.
The company has a strong potential for a significant spike, especially in the after-hours, and may reach $2 or even $3.

Bearish· Sep 25

The asset's ATM (at-the-money) option is from February, suggesting a lack of new developments.
The asset's price is expected to drop hard at open, with one post predicting a return to 60 cents and either a reverse split (R/S) or bankruptcy.
The asset's price is expected to break below the 1.7 resistance level, with one post suggesting that the price will continue to fall if this level is breached.

Generated by AI

Topics

Of the messages about AIFF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.85%	60.22%	40.43%
Technical Analysis	—	46.15%	39.78%	35.4%
Analysts	—	0%	0%	0.41%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.08%
Macro	—	0%	0%	23.68%

Announcements· Sep 25

Firefly Neuroscience, Inc. (NASDAQ: AIFF) has partnered with NeuroSigma to expand access to the Monarch eTNS System, the first FDA-cleared non-drug treatment for pediatric ADHD, through Firefly's nationwide network of Evoke clinician customers.
The partnership aims to increase clinician awareness of and access to the Monarch eTNS System, which is designed for children aged 7-12, and has a pre-launch waitlist of over 1,500 clinicians.
Firefly's stock price surged 31.08% to $1.56 after the announcement, with the company also launching a $7.43 million at-the-market (ATM) equity program in partnership with Konik Capital Partners.

Technical Analysis· Mar 26

$AIFF has cleared the first resistance and is expected to break 2.83, with 3 being imminent.
The stock has confirmed a powerful breakout with a $3.24 target, following a major Department of War partnership for deployment of its AI tech.
The 2-year chart shows the potential for $AIFF to retest previous highs if the right analyst drops a forward-looking justification, with the stock surging to $3.02 +79.76% due to its FDA-cleared EEG technology and DoD partnership for PTSD/TBI.

Generated by AI

Community

Of the messages about AIFF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	31.64%	33.48%	19.8%
Newcomers	100%	68.36%	66.52%	80.2%

Regulars· Sep 25

*Firefly (NASDAQ: AIFF) and NeuroSigma have partnered to expand access to the first FDA-cleared, non-drug treatment for pediatric ADHD, which could lead to a significant increase in the stock's value.
*The partnership and the potential for a spike in the after-hours trading session have been noted by regular participants, with some expressing excitement and others caution.
*The news has already resulted in a significant increase in trading volume, with the stock's price surging over 270 times its average daily volume.

Newcomers· Sep 28

The newcomer's focus is on the chart and trading activity of $AIFF, particularly the volume and momentum developing as the setup continues to unfold.
There is a strong technical bullishness and revenue growth in Firefly Neuroscience, with a 71.9% year-over-year quarterly revenue growth, and the company's AI-driven neuroscience platform adds a compelling technology angle to the move.
The asset's price action is worth tracking, with a strong recovery and potential for further growth, and the newcomer is watching for meaningful changes in volume and price action.

Generated by AI

News

Why Did Firefly Neuroscience Stock Soar Today? - Firefly Neuroscience (NASDAQ:AIFF)

Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.

4d agoBenzinga

12 Health Care Stocks Moving In Friday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), Apimeds P

Gainers Firefly Neuroscience (NASDAQ:AIFF) shares increased by 33.2% to $1.58 during Friday's regular session. The company's market cap stands at $18.6 million. Apimeds Pharmaceuticals (AMEX:APUS) shares moved

4d agoBenzinga

Firefly Neuroscience partners with NeuroSigma on ADHD treatment

5d agoInvesting.com

Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure

Detailed price information for Firefly Neuroscience Inc (AIFF-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Commercial momentum continues to build, while Firefly harnesses increased electrophysiological data combining EEG and ERG to unlock future valueKENMORE, N.Y., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence ("AI") company advancing precision neuroscience, today announced a close to four-fold (291%) year-over-year increase in Transcranial Magnetic Stimulation (“TMS”) center customer clinical assessments using its

1mo agoYahoo Finance

Firefly Neuroscience partners with Next Health on cognitive platform

2mo agoInvesting.com

Also Discussed

Investors talking about AIFF also mention

#	Name	Attention
1	Flash Sports & Media, Inc.UGRO	0%new
2	SGN - Signing Day Sports, Inc.	——
3	Agape Atp CorpATPC	0%0
4	Currenc Group Inc.CURR	0%new
5	BioAffinity Technologies Inc.BIAF	0%+0
6	BSLK - Bolt Projects Holdings, Inc.	——
7	Insight Acquisition Corp.AMOD	0%0
8	Gaxos.ai Inc.GXAI	0%0
9	Tevogen Bio Holdings Inc.TVGN	0%0
10	STAI - ScanTech AI Systems Inc.	——

Firefly Neuroscience Inc

Technology
Software - Application

Firefly Neuroscience Inc. is a medical technology and artificial intelligence company focused on neuroscientific solutions for mental illnesses and neurological disorders. Its core product is the FDA-cleared Brain Network Analytics platform, which analyzes EEG and ERP data to help clinicians evaluate brain function and support diagnostic and treatment decisions. The company’s offerings are designed for use in settings addressing conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and other cognitive or neurological disorders. Firefly Neuroscience also provides the Evoke System, a brain assessment tool that generates structured reports from neurophysiological data. The company serves clinicians and other healthcare professionals across North America, positioning itself within the growing field of digital brain health and precision neuroscience.

Website

Location

1100 Military Road

Kenmore, NY, 14217

United States

Social

What share of all stock conversation is about AIFF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0% +0	0% 0

Sep 28

The company's AI-driven neuroscience platform has shown strong revenue growth, with a 71.9% year-over-year quarterly increase.
The stock has broken out on strong volume and shown momentum, with a clean bullish pattern and RSI staying heated.
The $1.55 area has been decisively broken, with the stock surging to $2.01 on roughly 144M shares, and a next target of $2.10.

Generated by AI

Sentiment

Of the messages about AIFF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% +16.67	81.82% +41.82	80.41% +5.41	66.26% -8.96
Bearish	0% -16.67	18.18% -41.82	19.59% -5.41	33.74% +8.96

Bullish· Sep 25

$AIFF has broken out and is expected to continue its upward momentum.
Firefly Neuroscience's recent news is solid and has the potential to drive the stock price up to $3.50 by the end of Monday.
The company has a strong potential for a significant spike, especially in the after-hours, and may reach $2 or even $3.

Bearish· Sep 25

The asset's ATM (at-the-money) option is from February, suggesting a lack of new developments.
The asset's price is expected to drop hard at open, with one post predicting a return to 60 cents and either a reverse split (R/S) or bankruptcy.
The asset's price is expected to break below the 1.7 resistance level, with one post suggesting that the price will continue to fall if this level is breached.

Generated by AI

Topics

Of the messages about AIFF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	53.85%	60.22%	40.43%
Technical Analysis	—	46.15%	39.78%	35.4%
Analysts	—	0%	0%	0.41%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.08%
Macro	—	0%	0%	23.68%

Announcements· Sep 25

Firefly Neuroscience, Inc. (NASDAQ: AIFF) has partnered with NeuroSigma to expand access to the Monarch eTNS System, the first FDA-cleared non-drug treatment for pediatric ADHD, through Firefly's nationwide network of Evoke clinician customers.
The partnership aims to increase clinician awareness of and access to the Monarch eTNS System, which is designed for children aged 7-12, and has a pre-launch waitlist of over 1,500 clinicians.
Firefly's stock price surged 31.08% to $1.56 after the announcement, with the company also launching a $7.43 million at-the-market (ATM) equity program in partnership with Konik Capital Partners.

Technical Analysis· Mar 26

$AIFF has cleared the first resistance and is expected to break 2.83, with 3 being imminent.
The stock has confirmed a powerful breakout with a $3.24 target, following a major Department of War partnership for deployment of its AI tech.
The 2-year chart shows the potential for $AIFF to retest previous highs if the right analyst drops a forward-looking justification, with the stock surging to $3.02 +79.76% due to its FDA-cleared EEG technology and DoD partnership for PTSD/TBI.

Generated by AI

Community

Of the messages about AIFF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	31.64%	33.48%	19.8%
Newcomers	100%	68.36%	66.52%	80.2%

Regulars· Sep 25

*Firefly (NASDAQ: AIFF) and NeuroSigma have partnered to expand access to the first FDA-cleared, non-drug treatment for pediatric ADHD, which could lead to a significant increase in the stock's value.
*The partnership and the potential for a spike in the after-hours trading session have been noted by regular participants, with some expressing excitement and others caution.
*The news has already resulted in a significant increase in trading volume, with the stock's price surging over 270 times its average daily volume.

Newcomers· Sep 28

The newcomer's focus is on the chart and trading activity of $AIFF, particularly the volume and momentum developing as the setup continues to unfold.
There is a strong technical bullishness and revenue growth in Firefly Neuroscience, with a 71.9% year-over-year quarterly revenue growth, and the company's AI-driven neuroscience platform adds a compelling technology angle to the move.
The asset's price action is worth tracking, with a strong recovery and potential for further growth, and the newcomer is watching for meaningful changes in volume and price action.

Generated by AI

Firefly Neuroscience

Social

Sep 28

Bullish· Sep 25

Bearish· Sep 25

Announcements· Sep 25

Technical Analysis· Mar 26

Regulars· Sep 25

Newcomers· Sep 28

Why Did Firefly Neuroscience Stock Soar Today? - Firefly Neuroscience (NASDAQ:AIFF)

12 Health Care Stocks Moving In Friday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), Apimeds P

Firefly Neuroscience partners with NeuroSigma on ADHD treatment

Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience partners with Next Health on cognitive platform

Also Discussed

Firefly Neuroscience Inc

Company Information

Location

Why Did Firefly Neuroscience Stock Soar Today? - Firefly Neuroscience (NASDAQ:AIFF)

12 Health Care Stocks Moving In Friday's Intraday Session - Firefly Neuroscience (NASDAQ:AIFF), Apimeds P

Firefly Neuroscience partners with NeuroSigma on ADHD treatment

Firefly Neuroscience Expands Incentive Plan, Tightens Capital Structure

Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes

Firefly Neuroscience partners with Next Health on cognitive platform

Also Discussed

Social

Sep 28

Bullish· Sep 25

Bearish· Sep 25

Announcements· Sep 25

Technical Analysis· Mar 26

Regulars· Sep 25

Newcomers· Sep 28